Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Integration Host Factor IHF facilitates homologous recombination and mutagenic processes in Pseudomonas putida.

Mikkel K, Tagel M, Ukkivi K, Ilves H, Kivisaar M.

DNA Repair (Amst). 2020 Jan;85:102745. doi: 10.1016/j.dnarep.2019.102745. Epub 2019 Nov 5.

PMID:
31715424
2.

Acceleration of Diabetic Wound Healing with PHD2- and miR-210-Targeting Oligonucleotides.

Dallas A, Trotsyuk A, Ilves H, Bonham CA, Rodrigues M, Engel K, Barrera JA, Kosaric N, Stern-Buchbinder ZA, White A, Mandell KJ, Hammond PT, Mansbridge J, Jayasena S, Gurtner GC, Johnston BH.

Tissue Eng Part A. 2019 Jan;25(1-2):44-54. doi: 10.1089/ten.TEA.2017.0484. Epub 2018 Jun 29.

3.

A novel papillation assay for the identification of genes affecting mutation rate in Pseudomonas putida and other pseudomonads.

Tagel M, Tavita K, Hõrak R, Kivisaar M, Ilves H.

Mutat Res. 2016 Aug;790:41-55. doi: 10.1016/j.mrfmmm.2016.06.002. Epub 2016 Jul 6.

PMID:
27447898
4.

The ColRS signal transduction system responds to the excess of external zinc, iron, manganese, and cadmium.

Ainsaar K, Mumm K, Ilves H, Hõrak R.

BMC Microbiol. 2014 Jun 20;14:162. doi: 10.1186/1471-2180-14-162.

5.

Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.

Dallas A, Ilves H, Ma H, Chin DJ, Maclachlan I, Klumpp K, Johnston BH.

J Virol. 2014 May;88(9):4647-56. doi: 10.1128/JVI.00105-14. Epub 2014 Jan 29.

6.

Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.

Ma H, Dallas A, Ilves H, Shorenstein J, MacLachlan I, Klumpp K, Johnston BH.

Gastroenterology. 2014 Jan;146(1):63-6.e5. doi: 10.1053/j.gastro.2013.09.049. Epub 2013 Sep 27.

7.

Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice.

Dallas A, Ilves H, Shorenstein J, Judge A, Spitler R, Contag C, Wong SP, Harbottle RP, Maclachlan I, Johnston BH.

Mol Ther Nucleic Acids. 2013 Sep 17;2:e123. doi: 10.1038/mtna.2013.50.

8.

Mutation frequency and spectrum of mutations vary at different chromosomal positions of Pseudomonas putida.

Juurik T, Ilves H, Teras R, Ilmjärv T, Tavita K, Ukkivi K, Teppo A, Mikkel K, Kivisaar M.

PLoS One. 2012;7(10):e48511. doi: 10.1371/journal.pone.0048511. Epub 2012 Oct 31.

9.

Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing.

Dallas A, Ilves H, Ge Q, Kumar P, Shorenstein J, Kazakov SA, Cuellar TL, McManus MT, Behlke MA, Johnston BH.

Nucleic Acids Res. 2012 Oct;40(18):9255-71. doi: 10.1093/nar/gks662. Epub 2012 Jul 18.

10.

The ColRS system is essential for the hunger response of glucose-growing Pseudomonas putida.

Putrinš M, Ainelo A, Ilves H, Hõrak R.

BMC Microbiol. 2011 Jul 26;11:170. doi: 10.1186/1471-2180-11-170.

11.

The impact of ColRS two-component system and TtgABC efflux pump on phenol tolerance of Pseudomonas putida becomes evident only in growing bacteria.

Putrins M, Ilves H, Lilje L, Kivisaar M, Hõrak R.

BMC Microbiol. 2010 Apr 14;10:110. doi: 10.1186/1471-2180-10-110.

12.

Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity.

Ge Q, Ilves H, Dallas A, Kumar P, Shorenstein J, Kazakov SA, Johnston BH.

RNA. 2010 Jan;16(1):106-17. doi: 10.1261/rna.1894510. Epub 2009 Dec 1.

13.

Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.

Ge Q, Dallas A, Ilves H, Shorenstein J, Behlke MA, Johnston BH.

RNA. 2010 Jan;16(1):118-30. doi: 10.1261/rna.1901810. Epub 2009 Nov 30.

14.

Hairpin ribozyme-antisense RNA constructs can act as molecular Lassos.

Dallas A, Balatskaya SV, Kuo TC, Ilves H, Vlassov AV, Kaspar RL, Kisich KO, Kazakov SA, Johnston BH.

Nucleic Acids Res. 2008 Dec;36(21):6752-66. doi: 10.1093/nar/gkn637. Epub 2008 Oct 25.

15.

Stability study of unmodified siRNA and relevance to clinical use.

Hickerson RP, Vlassov AV, Wang Q, Leake D, Ilves H, Gonzalez-Gonzalez E, Contag CH, Johnston BH, Kaspar RL.

Oligonucleotides. 2008 Dec;18(4):345-54. doi: 10.1089/oli.2008.0149.

16.

ColRS two-component system prevents lysis of subpopulation of glucose-grown Pseudomonas putida.

Putrins M, Ilves H, Kivisaar M, Hõrak R.

Environ Microbiol. 2008 Oct;10(10):2886-93. doi: 10.1111/j.1462-2920.2008.01705.x. Epub 2008 Jul 24.

PMID:
18657172
17.

shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA.

Vlassov AV, Korba B, Farrar K, Mukerjee S, Seyhan AA, Ilves H, Kaspar RL, Leake D, Kazakov SA, Johnston BH.

Oligonucleotides. 2007 Summer;17(2):223-36.

PMID:
17638526
18.

Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model.

Wang Q, Ilves H, Chu P, Contag CH, Leake D, Johnston BH, Kaspar RL.

J Invest Dermatol. 2007 Nov;127(11):2577-84. Epub 2007 May 24.

19.

Inhibition of hepatitis C IRES-mediated gene expression by 8-17 deoxyribozymes in human tissue culture cells.

Vlassov AV, Ilves H, Johnston BH.

Dokl Biochem Biophys. 2006 Sep-Oct;410:257-9. No abstract available.

PMID:
17286096
20.

Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice.

Ilves H, Kaspar RL, Wang Q, Seyhan AA, Vlassov AV, Contag CH, Leake D, Johnston BH.

Ann N Y Acad Sci. 2006 Oct;1082:52-5.

PMID:
17145925
21.

The ColRS two-component system regulates membrane functions and protects Pseudomonas putida against phenol.

Kivistik PA, Putrins M, Püvi K, Ilves H, Kivisaar M, Hõrak R.

J Bacteriol. 2006 Dec;188(23):8109-17. Epub 2006 Sep 29.

22.
23.

Complete, gene-specific siRNA libraries: production and expression in mammalian cells.

Seyhan AA, Vlassov AV, Ilves H, Egry L, Kaspar RL, Kazakov SA, Johnston BH.

RNA. 2005 May;11(5):837-46.

24.
25.

IHF is the limiting host factor in transposition of Pseudomonas putida transposon Tn4652 in stationary phase.

Ilves H, Hõrak R, Teras R, Kivisaar M.

Mol Microbiol. 2004 Mar;51(6):1773-85.

26.
27.

Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus.

Berkowitz R, Ilves H, Lin WY, Eckert K, Coward A, Tamaki S, Veres G, Plavec I.

J Virol. 2001 Apr;75(7):3371-82.

28.

Gene transfer systems derived from Visna virus: analysis of virus production and infectivity.

Berkowitz RD, Ilves H, Plavec I, Veres G.

Virology. 2001 Jan 5;279(1):116-29.

29.
30.

Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication.

Veres G, Junker U, Baker J, Barske C, Kalfoglou C, Ilves H, Escaich S, Kaneshima H, Böhnlein E.

J Virol. 1998 Mar;72(3):1894-901.

31.

Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes.

Veres G, Escaich S, Baker J, Barske C, Kalfoglou C, Ilves H, Kaneshima H, Böhnlein E.

J Virol. 1996 Dec;70(12):8792-800.

32.

Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study.

Ilves H, Barske C, Junker U, Böhnlein E, Veres G.

Gene. 1996 Jun 1;171(2):203-8.

PMID:
8666273
33.
34.

Consecutive DNA terminator sequencing by using enzymatically generated primers.

Speek M, Ilves H, Lind A.

Anal Biochem. 1986 Nov 1;158(2):242-9.

PMID:
3028203

Supplemental Content

Support Center